Jim Cramer on Regeneron Pharmaceuticals, Inc. (REGN): ‘Stock That Seems To Have Disappointed People. Bizarre’

Insider Monkey01-16

We recently compiled a list of the Jim Cramer Discusses Joe Rogan, Elon Musk, And These 13 Stocks. In this article, we are going to take a look at where Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2503862272?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-16 00:29","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2503862272","market":"us","top_or_hot":-1,"title":"Jim Cramer on Regeneron Pharmaceuticals, Inc. (REGN): ‘Stock That Seems To Have Disappointed People. Bizarre’","media":"Insider Monkey","content":"<div>\n<p>We recently compiled a list of the Jim Cramer Discusses Joe Rogan, Elon Musk, And These 13 Stocks. In this article, we are going to take a look at where Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) ...</p>\n\n<a href=\"https://finance.yahoo.com/news/jim-cramer-regeneron-pharmaceuticals-inc-162901501.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Jim Cramer on Regeneron Pharmaceuticals, Inc. (REGN): ‘Stock That Seems To Have Disappointed People. Bizarre’</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJim Cramer on Regeneron Pharmaceuticals, Inc. (REGN): ‘Stock That Seems To Have Disappointed People. Bizarre’\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-01-16 00:29 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/jim-cramer-regeneron-pharmaceuticals-inc-162901501.html><strong>Insider Monkey</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>We recently compiled a list of the Jim Cramer Discusses Joe Rogan, Elon Musk, And These 13 Stocks. In this article, we are going to take a look at where Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) ...</p>\n\n<a href=\"https://finance.yahoo.com/news/jim-cramer-regeneron-pharmaceuticals-inc-162901501.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0058720904.USD","symbol_name":"联博国际健康护理基金A","start_time":0,"source_url":"https://finance.yahoo.com/news/jim-cramer-regeneron-pharmaceuticals-inc-162901501.html","article_id":"2503862272","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2503862272","pubTimestamp":1736958541,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"We recently compiled a list of the Jim Cramer Discusses Joe Rogan, Elon Musk, And These 13 Stocks.In this article, we are going to take a look at where Regeneron Pharmaceuticals, Inc.  stands against the other stocks.On the topic of markets, Cramer was appreciative of the fact that the market and equal-weighted benchmark S&P indexes are up identically over the last six months \"Well look I, that's good news actually. We want to have broader leadership,\" he remarked. However, without Wall Street's favorite AI stock, Cramer believes \"you have a market that's kind of ruthless. . . David, you know that this market survives on NASDAQ fuel and not on Dow fuel. And yet people sti","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0058720904.USD":"联博国际健康护理基金A","PSQ":"纳指反向ETF","LU2237438978.USD":"Amundi Funds US Pioneer A2 (C) USD","TSYW.SI":"TESLA 3xLongSG261006","LU0882574055.USD":"富达全球健康医疗A ACC","USJW.SI":"ALPHAB 3xLongSG261006","BK4570":"地缘局势概念股","TQQQ":"纳指三倍做多ETF","BK4585":"ETF&股票定投概念","REGN":"再生元制药公司","BK4139":"生物科技","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","LU2362541273.HKD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (HKD) ACC","LU2362541513.USD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (USD) ACC","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","LU0823416689.USD":"BNP PARIBAS HEALTH CARE INNOVATORS \"C\" (USD) ACC","LU1974910355.USD":"Allianz Thematica Cl AMg DIS USD","LU1917777945.USD":"安联专题基金Cl AT Acc","QLD":"纳指两倍做多ETF","SQQQ":"纳指三倍做空ETF","LU0053666078.USD":"摩根大通基金-美国股票A（离岸）美元","BK4588":"碎股","NVIW.SI":"NVDA 3xLongSG261006","QID":"纳指两倍做空ETF","LU2106854487.HKD":"ALLIANZ THEMATICA \"AMG\" (HKD) INC","PPI":"AXS Astoria Inflation Sensitive ETF","USAW.SI":"AMZN 3xLongSG261006","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","LU2023250504.SGD":"Allianz Thematica Cl AMg DIS H2-SGD",".IXIC":"NASDAQ Composite","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","LU2362540622.SGD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (SGDHDG) ACC"},"translate_title":"吉姆·克莱默(Jim Cramer)对再生元制药公司(REGN)表示：“这只股票似乎让人们失望了。奇怪的'","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"REGN":1,"PPI":1,".IXIC":0.9,"PSQ":0.6,"NVIW.SI":0.6,"QID":0.6,"QLD":0.6,"SQQQ":0.6,"TQQQ":0.6,"TSYW.SI":0.6,"USAW.SI":0.6,"USJW.SI":0.6,"MNQmain":0.6,"NQmain":0.6},"content_text":"We recently compiled a list of the Jim Cramer Discusses Joe Rogan, Elon Musk, And These 13 Stocks. In this article, we are going to take a look at where Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) stands against the other stocks.\nIn one of his latest appearances on CNBC's Squawk on the Street, Jim Cramer started the morning by commenting on the latest Producer Price Index (PPI) release. The PPI, which tracks inflation upstream of the supply chain, rose by 0.2% in December and fell short of economist expectations of 0.3%. However, this didn't lead to any significant reaction in the bond market. According to Cramer, \"Carl these, the bonds just don't want to react to anything good. Of course, we can immediately say, it's because we're gonna get a tough CPI number tomorrow. The fact is, is these numbers are tame. People have to start recognizing that there are some good numbers coming.\"\nHe shared other factors that might be fueling the bond market's performance. \"House prices coming down, food coming down, but it doesn't seem to matter,\" Cramer remarked. He added \"What the bonds are reacting to I think is a new administration, uh, concern about what is going to be, uh, tariffs, even though it looks like they're going to be phased in. You know David, interest rates don't wanna come down here. And they don't wanna come down there's too much issuance, there's a belief that the next administration is much more inflationary. And David it doesn't seem to matter what is printed, the bonds don't want to go higher. Interest rate's not low enough.\"\nAnother news that has made a lot of headlines recently is TikTok's fate in the US. Cramer believes that rather than a complete bank, there could \"be a gradual diminution of the service. In other words, it's not going to be turned off. I think that this whole idea that the Chinese Communist Party is really just a gigantic private equity firm leaves me cold. I just don't think that they are in a situation to broker a deal.\"\nOne person that the CNBC TV show host believes isn't discussed enough is electric vehicle billionaire Elon Musk. \"I mean, Carl, it's so exciting to talk about Elon Musk. I mean we haven't talked about Elon, you know you have to wait maybe to nine o' four to talk about Elon Musk. I just say we do it at the very top,\" believes Cramer. He added \"We have Elon Musk being the most important, well, he's, he's co-president right now which I think is a little absurd.. . . this man has become, Carl, a nation-state within. He's a state within a state.\"\nOn the topic of markets, Cramer was appreciative of the fact that the market and equal-weighted benchmark S&P indexes are up identically over the last six months \"Well look I, that's good news actually. We want to have broader leadership,\" he remarked. However, without Wall Street's favorite AI stock, Cramer believes \"you have a market that's kind of ruthless. . . David, you know that this market survives on NASDAQ fuel and not on Dow fuel. And yet people still insist on talking about the Dow.\"\nFinally, Cramer has also spent quite a bit of time discussing social media CEO Mark Zuckerberg's appearance on the Joe Rogan Experience podcast. This time around, he shared \"I'll go right to Joe Rogan. I'll be five hours in Joe Rogan. One of the most jarring things about the Joe Rogan interview was that he said he had to take a bathroom break. Well, there's professionalism personified.\" Cramer also commented on whether 38% is too much for an interviewer to speak. Taking a mixed view, he stated \"I think it is. I used to put a stopwatch to my show Kudlow & Cramer. I got to speak 38% of the time so you know what, maybe it's not so bad.\"\nOur Methodology\nTo make our list of the stocks that Jim Cramer talked about, we listed down all the stocks he mentioned during CNBC’s Squawk on the Street aired yesterday.\nFor these stocks, we also mentioned the number of hedge fund investors. Why are we interested in the stocks that hedge funds invest in? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 275% since May 2014, beating its benchmark by 150 percentage points. (see more details here).\n A pharmacist in a lab coat carefully analyzing a vial of medicine for its quality. \nRegeneron Pharmaceuticals, Inc. (NASDAQ:REGN)\nNumber of Hedge Fund Holders In Q3 2024: 62\nRegeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is a New York-based biotechnology company that develops medicines for eye diseases, dermatitis, asthma, and other ailments. One of the firm's most important products is its treatment for age-related macular degeneration. The drug is called Eyelea, and it is key to Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)'s hypothesis as was evident in October last year when the shares dropped by 9% after a higher dose variant of the drug missed analyst sales estimates. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)'s shares are down by 3.4% year-to-date, and here's what Cramer said about the stock:\n\n\"I'll be doing Regeneron, which is another stock that seems to have disappointed people. Bizarre.\"\n\nOverall REGN ranks 8th on our list of the stocks Jim Cramer recently discussed. While we acknowledge the potential of REGN as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter timeframe. If you are looking for an AI stock that is more promising than REGN but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.   \nREAD NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock.   \nDisclosure: None. This article is originally published at Insider Monkey.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.30.2","shortVersion":"4.30.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2503862272"}